Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

H1-antihistamines in children.

F Estelle R Simons1

  • 1University of Manitoba, Winnipeg, Manitoba, Canada.

Clinical Allergy and Immunology
|July 13, 2002
PubMed
Summary

H1-antagonists effectively treat allergic rhinoconjunctivitis in children. However, newer, non-sedating options are preferred over older ones, except in specific severe cases like intractable itching or anaphylaxis.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Changing the history of anaphylaxis mortality statistics through the World Health Organization's International Classification of Diseases-11.

The Journal of allergy and clinical immunology·2019
Same author

Guiding Principles for the Recognition, Diagnosis, and Management of Infants with Anaphylaxis: An Expert Panel Consensus.

The journal of allergy and clinical immunology. In practice·2019
Same author

Critical view of anaphylaxis epidemiology: open questions and new perspectives.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2018
Same author

Adherence with epinephrine autoinjector prescriptions in primary care.

Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology·2017
Same author

Uptake of EpiPen and Allerject (Auvi-Q) epinephrine auto-injectors in Manitoba children.

Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology·2017
Same author

Are dispensing patterns for epinephrine autoinjectors age-appropriate in children?

The journal of allergy and clinical immunology. In practice·2017

Area of Science:

  • Pediatric Allergy and Immunology
  • Pharmacology
  • Clinical Therapeutics

Background:

  • H1-antagonists are widely used in pediatric populations for allergic conditions.
  • Evidence supports their efficacy in allergic rhinoconjunctivitis but not broadly for other common childhood illnesses.
  • Safety and efficacy profiles vary significantly between first-generation and second-generation H1-antagonists.

Purpose of the Study:

  • To review the evidence for H1-antagonist use in pediatric allergic and non-allergic conditions.
  • To delineate appropriate uses and contraindications for first- and second-generation H1-antagonists in children.
  • To highlight the benefits of newer, non-sedating H1-antagonists in pediatric care.

Main Methods:

  • Systematic review of pediatric clinical trials and evidence-based guidelines.
  • Analysis of pharmacokinetic and pharmacodynamic data for different H1-antagonist generations.
  • Evaluation of adverse event profiles, particularly central nervous system (CNS) effects.

Main Results:

  • Strong evidence supports H1-antagonist use for pediatric allergic rhinoconjunctivitis.
  • Limited scientific rationale exists for their use in upper respiratory infections or otitis media.
  • First-generation H1-antagonists can impair CNS function; their use should be restricted to severe pruritus or anaphylaxis.
  • Second-generation H1-antagonists are recommended for most pediatric allergic conditions due to their safety profile.

Conclusions:

  • Second-generation H1-antagonists (cetirizine, fexofenadine, loratadine) are the preferred choice for children due to minimal CNS side effects.
  • First-generation H1-antagonists should be used judiciously in specific pediatric cases.
  • Further research is needed on the role of H1-antagonists in preventing asthma development in high-risk infants.

Related Experiment Videos